Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5.6% – Time to Buy?

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shot up 5.6% on Thursday . The stock traded as high as $83.98 and last traded at $84.05. 539,935 shares were traded during trading, a decline of 48% from the average session volume of 1,032,575 shares. The stock had previously closed at $79.61.

Analysts Set New Price Targets

Several brokerages recently weighed in on DNTH. HC Wainwright lifted their price objective on Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, March 9th. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Robert W. Baird lifted their target price on shares of Dianthus Therapeutics from $67.00 to $132.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 9th. Finally, Oppenheimer upped their price target on shares of Dianthus Therapeutics to $145.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Dianthus Therapeutics has an average rating of “Moderate Buy” and an average target price of $117.30.

Dianthus Therapeutics Stock Up 3.7%

The company has a market capitalization of $3.67 billion, a PE ratio of -20.27 and a beta of 1.56. The company has a 50-day moving average price of $58.79 and a two-hundred day moving average price of $45.74.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%.The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.40 million. As a group, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Insider Transactions at Dianthus Therapeutics

In related news, CAO Edward Carr sold 43,682 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Simrat Randhawa sold 33,830 shares of the stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $81.48, for a total transaction of $2,756,468.40. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 200,430 shares of company stock valued at $16,332,702. 8.15% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in shares of Dianthus Therapeutics in the second quarter worth $27,000. Parkside Financial Bank & Trust grew its position in Dianthus Therapeutics by 131.7% during the third quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after buying an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Dianthus Therapeutics in the 4th quarter worth about $40,000. Russell Investments Group Ltd. purchased a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after acquiring an additional 3,317 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.